Why Elizabeth Holmes Is in Prison as New Theranos Documentary Renews Interest in Her Fraud Case

A new documentary about convicted Theranos founder Elizabeth Holmes is renewing interest in one of Silicon Valley’s most closely watched criminal fraud cases more than three years after she reported to federal prison.

You Can See Everything, a nearly three-hour film directed by Nathan Fielder and Lance Oppenheim, made a surprise debut at the Telluride Film Festival on September 6. The documentary begins 34 days before Holmes entered prison in May 2023 and follows the former technology executive as she maintains her innocence before beginning her sentence. A24, which is distributing the film, lists it for release in 2026.

The renewed attention has placed Holmes and Theranos back in the public spotlight, but the criminal case that put her in prison involved a more specific question than whether the company’s much-promoted blood-testing technology worked.

Holmes was convicted of deliberately deceiving investors about Theranos and its technology in order to obtain their money.

A federal jury in San Jose found Holmes guilty in January 2022 of one count of conspiracy to commit wire fraud against Theranos investors and three counts of wire fraud involving individual investors. The wire transfers underlying those three counts totaled more than $140 million.

U.S. District Judge Edward Davila later sentenced Holmes to 135 months, or 11 years and three months, in federal prison. She also received three years of supervised release following imprisonment. Holmes began serving her sentence on May 30, 2023, at Federal Prison Camp Bryan in Texas, where she remains incarcerated.

At its peak, Theranos promised to transform laboratory medicine by performing a wide range of medical tests using only a small amount of blood collected through a finger stick.

The company attracted prominent investors and business partners and at one point carried a valuation of approximately $9 billion. Holmes became one of Silicon Valley’s most recognizable entrepreneurs and was portrayed publicly as the founder of a technology capable of changing the way blood testing was performed.

Federal prosecutors later presented evidence showing a very different picture inside the company.

According to the Justice Department, Holmes knew Theranos’ proprietary analyzer could perform only a limited number of tests and had problems producing accurate and reliable results. Theranos frequently relied instead on conventional laboratory machines, even as Holmes continued presenting the company’s own technology as capable of performing most or all of its testing.

Prosecutors also showed that Holmes made false or misleading statements to investors about outside validation of Theranos’ technology.

Holmes represented that major pharmaceutical companies had extensively evaluated and validated Theranos technology. Investors were shown reports bearing pharmaceutical company logos that prosecutors said falsely suggested endorsements.

She also claimed Theranos technology had been deployed by the U.S. military in battlefield settings and had generated significant business with the Department of Defense. Trial evidence showed that the technology had not been used to treat soldiers on the battlefield and that Theranos received little revenue from military-related testing.

Financial projections became another part of the government’s case.

Holmes told investors that Theranos was positioned for dramatic revenue growth. Prosecutors said she presented projections exceeding $100 million in annual revenue and eventually approaching $1 billion while knowing that the company’s actual financial performance was far weaker. Theranos had no revenue in 2012 and 2013, according to the government.

The distinction between what happened to investors and what happened to patients is important when explaining Holmes’ conviction.

Federal prosecutors charged Holmes with schemes involving both groups. Her indictment included allegations that investors were deceived into putting money into Theranos and that patients were misled into purchasing the company’s blood-testing services.

The jury did not convict Holmes of defrauding patients.

Jurors acquitted her of the conspiracy charge involving patients and three substantive patient-related wire fraud counts. Another patient-related count had been dismissed during trial. The jury also failed to reach unanimous verdicts on three additional investor-fraud counts.

Her four convictions were all tied to investors.

Patient experiences nevertheless played an important role in demonstrating problems with Theranos’ technology. Prosecutors presented evidence that inaccurate results affected patients undergoing testing involving cancer, pregnancy and other medical conditions. Theranos ultimately voided all tests performed using its proprietary analyzer, according to the Justice Department.

Holmes maintained at trial that she did not intend to defraud investors.

She testified in her own defense and acknowledged mistakes while disputing the government’s contention that she knowingly committed fraud. She also testified about her relationship with former Theranos president and chief operating officer Ramesh “Sunny” Balwani, alleging that he emotionally and sexually abused her and exercised control over aspects of her life. Balwani denied those allegations.

Balwani was tried separately and convicted on all 12 fraud and conspiracy counts brought against him. He received a 155-month federal prison sentence.

Holmes continued challenging her conviction after entering prison.

The U.S. Court of Appeals for the Ninth Circuit rejected her appeal and upheld her conviction, sentence, and restitution order. Holmes argued, among other things, that the trial court improperly allowed some former Theranos employees to offer testimony that amounted to undisclosed expert testimony and improperly restricted portions of her cross-examination of a former laboratory director.

The appellate court concluded that the challenged rulings did not justify overturning the verdict.

Holmes also challenged the financial consequences of her conviction.

Davila ordered Holmes and Balwani jointly responsible for more than $452 million in restitution to 14 victims, including Theranos investors, Safeway and Walgreens. The Ninth Circuit acknowledged a potential issue with part of the district court’s restitution methodology but found any error harmless because the investors ultimately could not recover value from their Theranos shares. It affirmed the restitution order in full.

Her court appeal has therefore not changed the conviction or sentence.

Holmes has since turned to another possible avenue for reducing her time in prison: presidential clemency.

She applied to President Donald Trump for a commutation of her sentence. The request remained pending as of recent reporting. A commutation could reduce or eliminate the remaining prison term without overturning Holmes’ conviction. It would differ from a presidential pardon and would not, by itself, erase the underlying judgment against her.

Holmes’ projected release date has moved forward as federal prison credits have been applied. Bureau of Prisons information cited by news organizations this week places her anticipated release in 2030, although projected federal release dates can change.

Holmes continues to dispute the criminal case against her, but her present legal status is unchanged.

A jury convicted her of four federal felonies. The trial judge sentenced her to more than 11 years in prison. The Ninth Circuit upheld the convictions, sentence, and $452 million restitution order.

The new interest surrounding Holmes may reopen public debate over Theranos and one of Silicon Valley’s most famous corporate failures. Legally, the reason Holmes remains in federal prison is narrower: jurors found beyond a reasonable doubt that she knowingly participated in a scheme to deceive investors about Theranos and obtained their money through wire fraud.